Only medications that inhibit cholesteryl ester transfer protein (CETP), angiopoietin-related protein 3 (ANGPTL3), and apolipoprotein C-III (apoC-III) have lately been explored in clinical trials, despite the fact that about 80 genes are linked to hypercholesterolemia. Here, CETP is linked to familial hypercholesterolemia.